This issue's Image Section graphically illustrates a model for one of the main findings in the positron emission tomography study by . Dopamine competes with the radiotracer [ 11 C]raclopride for neostriatal dopamine D 2 receptors. With treatment using the tyrosine hydroxylase inhibitor alpha-methyl-para-tyrosine (AMPT; 5250 mg orally over 29 h), dopamine levels are reduced, and more D 2 receptors become available for [ 11 C]raclopride to bind to. In six healthy subjects, AMPT treatment decreased levels of the dopamine metabolite homovanillic acid significantly by 62 ± 17% (average ± standard deviation). The D 2 receptor binding potential, ie the product of D 2 receptor density and affinity, increased significantly by 13.3 ± 5.9%. The mechanism by which dopamine depletion 'unmasks' D 2 receptors could, besides direct competition, involve D 2 receptor trafficking from cytosol to cell membrane.
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